Join A Cure in Sight on The Eye Believe Podcast and various research experts and clinicians who attended American Society of Clinical Oncology (ASCO) Conference early June 4-6, 2022, as well as the 20th Congress of the International Society of Ocular Oncology (ISOO), June 17-21, 2022. A Cure in Sight attended both to gather updates in research and present a united, collaborative front for the sake of patient advocacy in the field of ocular melanoma.

In this episode, you’ll hear from the experts about what’s new in ocular melanoma and uveal melanoma. You’ll also hear news of new clinical trials, and upcoming expanded access programs for treatments for metastatic uveal melanoma.

Tune in for updates from:


Jerry Wu with Ascentage Pharma, focused on an abstract from Dr. Meredith McKean of the Sarah Cannon Cancer Center in Nashville discussing a novel cancer treatment for uveal melanoma called APG-115. Search “APG-115 melanoma” on ascentage.com, or listed on clinicaltrials.gov.

Dr. Johnny John from Delcath discusses the presentation of data from the FOCUS Trial at ASCO and the opening of Delcath’s Expanded Access Program for patients with Metastatic Ocular Melanoma. Information on EAP sites may be found on  https://delcath.com/clinical-trials/expanded-access-program/

Karin Hellsvik with Foghorn Therapeutics, discussing uveal melanoma patient advocacy, as well as the existing study for uveal melanoma patients, found by searching FHD-286 on clinicaltrials.gov.
 
Dr. Justin Moser with HonorHealth Research and Innovation Institute in Scottsdale AZ, discussing a new West Coast clinical trial for metastatic uveal melanoma patients. Info on this trial can be found here:
https://clinicaltrials.gov/ct2/show/NCT05004025

Danet Peterson, sharing about her personal ocular melanoma journey in a brief ASCO interview with i3Health.
 
Dr. Cadmus Rich with Aura Biosciences discussing the AU-011 (belzupacap serotalocan) program, including an upcoming pivotal study for primary choroidal melanoma treatment. Search AU-011 on clinicaltrials.gov for more info.

Dr. Johnny John from Delcath along with Dr. Ellen Kapiteijn and Dr. Thaïs Tong from the Leiden University Medical Center discusses the presentation of data from the Chopin Trial in which Delcath’s percutaneous hepatic perfusion treatment is combined with immunotherapy for patients with Metastatic Ocular Melanoma. Preliminary data from the trial was presented at the ASCO conference and was also presented at the ISOO conference.
 
Steven Katz, Chief Medical Officer at TriSalus Life Sciences discussing early safety data from the PERIO-01 clinical study. See www.periotrial.com for more info.

ANNOUNCEMENTS:

Lookin’ For a Cure Arizona 5K Walk for Ocular Melanoma 
COMING UP September 24, 8 AM 
Register here and be sure to bring friends and family to walk with us! (Virtual option coming soon)

Eye Believe Survivorship Seminar in Nashville, Tennessee
October 14-15. REGISTER HERE! (Welcome reception for in person attendees on October 13, 6:00 PM)
(Virtual and in person options.)

Lookin’ For a Cure TEXAS 5K Walk for Ocular Melanoma 
NOVEMBER 5, 2022; 8 AM 
Register here and be sure to bring friends and family to walk with us! (Virtual option available)

Email contact@acureinsight.org for questions regarding the event!

*********
Be sure to follow us on Facebook, Twitter, Linked In, or  Instagram @acureinsight, for more stories, tips, research news, and ideas to help you navigate this journey with OM!
*A Cure in Sight is a 501c3 organization. All donations made can help fund our podcast to educate patients, fund research, aid patients, and more!

Donate $10 $15 $20 today to help A Cure in Sight in their quest to find a cure.

Contribute via  PAYPAL OR VENMO or reach out directly to contact@acureinsight.org 
The Eye Believe Podcast is brought to you by Castle Biosciences. Castle Biosciences is a leading diagnostics company improving health through innovative tests that guide patient care. The Company a